잠시만 기다려 주세요. 로딩중입니다.

Retrospective evaluation of toceranib phosphate (Palladia) for treatment of different tumor types in 31 dogs

대한수의학회지 2021년 61권 1호 p.10 ~ 10
최서인, 남예림, 김진경, 박형진, 송근호, 서경원,
소속 상세정보
최서인 ( Choi Seo-In ) - Chungnam National University College of Veterinary Medicine Department of Veterinary Internal Medicine
남예림 ( Nam Ye-Lim ) - Haemaru Referral Animal Hospital
김진경 ( Kim Jin-Kyoung ) - Haemaru Referral Animal Hospital
박형진 ( Park Hyung-Jin ) - Sungsim Animal Medical Center
송근호 ( Song Kun-Ho ) - Chungnam National University College of Veterinary Medicine Department of Veterinary Internal Medicine
서경원 ( Seo Kyoung-Won ) - Chungnam National University College of Veterinary Medicine Department of Veterinary Internal Medicine

Abstract


The purpose of this retrospective study was to provide additional data on the use of toceranib in a wide variety of tumor types in small breed dogs, especially < 8 kg (except 5 dogs). This was a retrospective study of 31 dogs with malignant tumors treated with a 2.5 mg/kg median dose of toceranib (Palladia; Zoetis, USA) on a Monday-Wednesday-Friday schedule. Clinical benefit was observed in 13 of 15 dogs (86.7%, 3 with complete response, 4 with partial response, 6 with stable disease) with gross disease. Distant metastasis, response to treatment, and treatment setting were significantly associated with survival time. Negative prognostic factors were multiple chemotherapy and distant metastasis (affecting progression-free survival [PFS]), surgery, regional enlarged lymph nodes, underlying disease, and toxicity (affecting median survival time [MST]). Positive prognostic factors were epithelial and round cell tumor (affecting PFS), epithelial tumor, microscopic disease, no evidence of disease response, and stable disease (MST). In conclusion, a clinical benefit from toceranib treatment was noted in most of the dogs with gross disease in our study. This study suggested that the toceranib is probably selective treatment to various tumor types in small breed dogs.

키워드

canine; neoplasms; Palladia; toceranib phosphate; tyrosine kinase inhibitor

원문 및 링크아웃 정보

등재저널 정보